Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

The Quick Take
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Off-Broadway Production DUST Raises $30,000 for Young Adults with Autism
LOS ANGELES, Nov. 7, 2026 /PRNewswire/ -- The Off-Broadway production DUST raised $30,000 to support young adults with autism in partnership with Cultural…
Business
Clough Global Opportunities Fund director buys $1,996 in GLO shares
Business
How #Amazon's low prices raises #prices. #soexpensive
------------------------------------------------------ Business Insider is a global newsroom covering business, technology, innovation, and the economy. Visit…
Business
